CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 233 enrolled
Drug / intervention
Camrelizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04346381
NCT04346381Phase 2Completed
CompareCT.gov

An Open-label, Multi-center，Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Apr 15, 2020·Updated Sep 18, 2023

In Brief

A Phase 2 clinical trial evaluating Camrelizumab and Famitinib for Solid Tumor. Completed, enrolled 233 participants across 1 site.

Detailed Summary

This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 15, 2020
Enrollment StartJun 5, 2020
Primary CompletionJun 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.2 years ago

Interventions

Camrelizumabdrug

Intravenous (IV) camrelizumab on Day 1 of each cycle

Famitinibdrug

famitinib po qd